RTTNews | Dec 20, 2021 08:01AM EST

08:01 Monday, December 20, 2021 (RTTNews.com) - Can-Fite BioPharma Ltd. (CANF) said the last patient treated under an Open Label Extension program of its concluded phase II study of Namodenoson in the treatment of hepatocellular carcinoma reported a Complete Response. The patient has now survived five years, and completed clearance of all cancer lesions.

In the first quarter of 2022, Can-Fite plans to begin patient enrollment in its phase III trial for Namodenoson in the treatment of patients with advanced hepatocellular carcinoma with underlying Child Pugh B7 cirrhosis to support a NDA.

Shares of Can-Fite BioPharma were up 63% in pre-market trade on Monday.

Read the original article on RTTNews ( https://www.rttnews.com/3250530/can-fite-complete-response-of-hcc-observed-in-patient-treated-with-namodenoson.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved